Musculoskeletal Inflammatory Clinical Trial
Official title:
ARTERIAL EMBOLIZATION OF PERSISTENT GENICULATE ARTERIES FOR CHRONIC PAIN MANAGEMENT AFTER TOTAL KNEE-REPLACEMENT ARTHROPLASTY: A FEASIBILITY STUDY (KNEE EMBOLISATION)
Recent works in interventional radiology have shown interesting results in the treatment of musculoskeletal inflammatory sites by arterial embolization. Supra-selective arterial embolization has been successfully developed by Dr. Okuno (Japan) to manage moderate to severe knee osteoarthritis. Also, inflammation of the surgical site mediated via geniculate arteries is a major cause for persistent chronic post-operative gonalgia.
| Status | Recruiting |
| Enrollment | 24 |
| Est. completion date | February 2024 |
| Est. primary completion date | August 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Adult patient (male or female) aged 18-85 - Suffering from moderate to severe chronic pain (EVA > 50mm) more than 6 months after total prosthetic knee replacement surgery for severe gonarthrosis with impact on quality of life. - And having followed for at least 3 months a well-conducted conservative medical treatment (anti-inflammatory, analgesic, masso-kinesiotherapy). - The patient may initially have had a single or bilateral replacement. The period of 6 months must be respected for each side, between the intervention and the inclusion for homolateral pain. - Patient willing to participate in the study and with signed informed consent. - Patient willing to undergo post-operative monitoring for one year. Exclusion Criteria: Orthopaedic or rheumatological pathologies: - Rheumatoid arthritis - Psoriatic rheumatism - Spondylarthropathies - History of primary or secondary bone tumor, in remission or active. - Myeloma - Operational criteria: - Infection of the surgical site - Re-operation - Severe bleeding - Use of turnstile per-operative - Wound of popliteal artery - Diabetic patient - Comorbidities: - General condition responsible for objective hemostasis disorder (hemophilia, Willebrand disease, thrombocytopenia) and anticoagulant treatments. - Pads 100 G/L |
| Country | Name | City | State |
|---|---|---|---|
| France | Assistance Publique Hopitaux de Marseille | Marseille |
| Lead Sponsor | Collaborator |
|---|---|
| Assistance Publique Hopitaux De Marseille |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | arterial embolization | 12 MONTHS | ||
| Secondary | VAS pain score | 12MONTHS | ||
| Secondary | Western Ontario and Universities Osteroarthritis Index (WOMAC) score | 12MONTHS | ||
| Secondary | SF36 quality of life score | 12 MONTHS |